Improving outcomes in type 2 diabetes; a role for GLP-1 RA?
Despite recent advances in glucose-lowering therapies, rates of cardiovascular disease and mortality in people with type 2 diabetes, about 90% of whom have obesity or overweight, still remain high. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven good efficacy in glycaemic control and weight loss in patients with T2D. Furthermore, recent cardiovascular outcome trials suggest that a few GLP-1RAs have demonstrated cardiovascular benefits in patients with T2D and established or high-risk cardiovascular disease, resulting in recent updates of treatment labels and national and international guidelines.
In this session, Dr Seidu will give an overview of different GLP-1RA therapies and their place in the treatment pathway for patients with T2D and high cardiovascular risk.
- To discuss the link between type 2 diabetes, obesity and cardiovascular disease
- To provide an overview of recent cardiovascular outcome trial results
- To describe the different GLP-1RAs therapies available and discuss their optimal placing in the management of patient with type 2 diabetes and high cardiovascular risk
This session has been organised and funded by Novo Nordisk
Thursday 15th November 2018
15:55 - 16:25
Primary, Community & Specialist Care